Solid Biosciences is a life science company focused on advancing a portfolio of neuromuscular and cardiac programs for the treatment of devastating diseases, including Duchenne, Friedreich’s ataxia, BAG3 mediated dilated cardiomyopathy, and additional cardiac diseases. We aim to be the center of excellence across the entire disease spectrum, serving as a catalyst to bring together those with the expertise in science, technology, disease management and care. Disease-focused and founded by a family directly impacted, our mandate is simple yet comprehensive - attack the roots of the disease and improve daily life for patients. Solid is headquartered in Charlestown, MA, USA.